Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
$62.25
$0.53(0.67%)
At close: 4:00 PM EST
$62.25
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $89.98
Previous CloseN/A
Volume488.69K
Average Volume (3M)4.41M
Market Cap
$23.96B
Enterprise Value$24.75B
Total Cash (Recent Filing)$2.00B
Total Debt (Recent Filing)$1.39B
Price to Earnings (P/E)31.0
Beta1.13
Next Earnings
Apr 23, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding384,864,840
10 Day Avg. Volume4,566,510
30 Day Avg. Volume4,405,734
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)9.43
Price to Sales (P/S)5.56
P/FCF Ratio24.04
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue5.31
Enterprise Value/Gross Profit8.83
Enterprise Value/Ebitda18.52
Forecast
1Y Price Target
$86.76Price Target Upside39.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)2.49
Revenue Forecast (FY)$5.23B
Bulls Say, Bears Say
Bulls Say
Coverage ExpansionPotential Medicare coverage for non-insulin type 2 patients could materially expand the addressable market and drive meaningful volume growth, supported by clinical trial readouts and a patient outcomes registry.
International Expansion And SoftwareStronger international revenue trends and rollout of the Stelo app platform are increasing new patient starts abroad and could allow overseas markets to grow faster than the United States.
Product Adoption And MarginsWider adoption of the redesigned G7 sensor and the introduction of longer‑wear sensors are improving reliability and utilization, supporting higher margins through better manufacturing efficiency and lower scrap rates.
Bears Say
Guidance And Growth RiskManagement's revenue outlook is slightly below certain analyst projections, which could temper upside expectations if patient and prescriber adoption does not accelerate.
Operational And Confidence RisksRamp-up of a new manufacturing facility combined with a prior reliability controversy may disrupt operations, press margins during the transition, and reduce patient and provider confidence.
Profitability PressureGross margin results and management guidance point to pressure on product profitability, with forecasts implying lower profit margins than some analyst models anticipate.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $89.98 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $23.96B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Apr 23, 2026 which is in 25 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Feb 12, 2026. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.46.
How many shares outstanding does Dexcom have?
Dexcom has 384,864,840 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.68 in its last earnings report, beating expectations of $0.65. Following the earnings report the stock price went up 7.591%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.76 (39.37% Upside)
$86.76 (39.37% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 77%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.39%
12-Months-Change
Fundamentals
Return on Equity
32.44%
Trailing 12-Months
Asset Growth
-2.23%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
DXCM Company Deck
DXCM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational recovery, solid revenue and margin improvement, robust cash generation, and several product and commercialization catalysts (G7 15-day, Smart Basal, Stelo, EHR integration). Management acknowledged prior supply/sensor deployment issues but demonstrated clear remediation and sequential margin recovery. Near-term headwinds include ramp-related OpEx for the Ireland facility, Q1 cadence seasonality, and uncertainty around CMS timing and competitive/payer dynamics, but these are framed as manageable or temporary. Overall the positives (growth, margin expansion, cash, product momentum) materially outweigh the headwinds.View all DXCM earnings summariesDXCM Revenue Breakdown
71.53% U.S.
28.47% International
DXCM Stock 12 Month Forecast
Average Price Target
$86.76
▲(39.37% Upside)
Technical Analysis
Ownership Overview
0.54% Insiders
24.29% Mutual Funds
20.59% Other Institutional Investors
20.80% Public Companies and Individual Investors